9MW-1111 is under clinical development by Mabwell Shanghai Bioscience and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how 9MW-1111’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
9MW-1111 is under development for the treatment of advanced and metastatic solid tumors and Her 2 negative advanced breast cancer. It is administered through parenteral route. It acts by targeting programmed cell death protein 1 (PD1).
Mabwell Shanghai Bioscience overview
Mabwell Shanghai Bioscience is a company that is focused on the discovery and industrialization of therapeutic monoclonal antibody, innovative vaccines and long-acting cytokine drugs. The company is headquartered in Shanghai, China.
For a complete picture of 9MW-1111’s drug-specific PTSR and LoA scores, buy the report here.